Simple benchmark for complex dose finding studies-Reference-Cited by-同舟云学术

Simple benchmark for complex dose finding studies

Published:2014-02-25 Issue:2 Volume:70 Page:389-397
ISSN:0006-341X
Container-title:Biometrics
language:en
Short-container-title:Biom

Author:

Cheung Ying Kuen¹

Affiliation:

1. Department of Biostatistics, Mailman School of Public Health; Columbia University; New York, New York 10032 U.S.A.

Funder

National Institutes of Health

Publisher

Wiley

Subject

Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/biom.12158/fullpdf

Reference22 articles.

1. Dose finding based on multiple toxicities in a soft tissue sarcoma trial;Bekele;Journal of the American Statistical Association,2004

2. The bivariate continual reassessment method

3. Coherence principles in dose finding studies;Cheung;Biometrika,2005

4. Sequential implementation of stepwise procedures identifying the maximum tolerated dose;Cheung;Journal of the American Statistical Association,2007

5. Stochastic approximation and modern model-based designs for dose finding clinical trials;Cheung;Statistical Science,2010

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes;ESMO Open;2024-07

2. A new function for drug combination dose finding trials;Scientific Reports;2024-02-12

3. Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression;Statistics in Medicine;2022-10-19

4. Patient-specific dose finding in seamless phase I/II clinical trials;Sequential Analysis;2022-07-03

5. CFO: Calibration-free odds design for phase I/II clinical trials;Statistical Methods in Medical Research;2022-03-03